Advanced gastric cancer remains one of the deadliest malignancies, with a 5-year overall survival rate below 10%. In recent years, combining chemotherapy with PD-1 or PD-L1 inhibitors has become standard first-line care for previously untreated HER2-negative disease. Yet major global trials and subgroup analyses have pointed to a recurring pattern: Asian patients often experience stronger … Read more
Neutrophil infiltration is a hallmark of pulmonary inflammation during respiratory viral infections, yet the origin of these cells has been a subject of debate. Using a golden hamster model of SARS-CoV-2 infection, the study led by Professor Xuetao Cao’s team at the Chinese Academy of Medical Sciences unveiled a dynamic spleen-to-lung neutrophil axis that operates … Read more
Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and limited responses to immunotherapy in most patients. Although immune checkpoint inhibitors have transformed treatment for certain tumor subtypes, the majority of colorectal cancers remain “immune-cold,” meaning they fail to trigger effective anti-tumor immunity. Increasing evidence suggests that tumor-associated … Read more
For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell killing. However, growing clinical and single-cell sequencing evidence shows that CD4+ T cells are far more than immune “helpers.” Within tumors, CD4+ T cell subsets exhibit remarkable heterogeneity, ranging from cytotoxic CD4+ CTLs to immunosuppressive regulatory … Read more
A new molecular analysis reveals that many patients labeled as cockroach-allergic may actually be reacting to shared proteins found across mites, seafood, and insects, highlighting the need for more precise allergy diagnostics. Study: Cockroach sensitization and its hidden links to mite and food allergens. Image Credit: kaninw / Shutterstock A recent study published in Scientific Reports … Read more
Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) support the potential of new therapies that could improve clinical outcomes for patients with squamous and adenocarcinoma non-small cell lung cancers (NSCLC) that don’t respond … Read more
Cells in our immune system are best known for providing security against external invaders such as bacteria and viruses. These immune cells also guard against internal threats, including cancerous tumors. Different forms of cancer cells and tumors have their own tricks for avoiding detection by the body’s security system altogether or otherwise sabotaging any attempts … Read more
SEATTLE – March 4, 2026 – Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. March is the awareness month for colorectal cancer and multiple myeloma. If you’re interested in speaking to experts, contact [email protected] to schedule interviews. Infectious disease research Scientists develop first-of-its-kind antibody to block Epstein-Barr … Read more
Competing interests M.S.v.d.H. has received institutional funding from Bristol Myers Squibb to finance the INDIBLADE trial.… The post Ipilimumab & Nivolumab for Muscle-Invasive Bladder Cancer: Phase 2 Trial appeared first on Archynetys. Source link
Unlike some other forms of lymphoma, advanced stage follicular lymphoma is considered incurable. But a new analysis of long-term data on patients treated for the disease years ago with standard regimens of immunotherapy and a chemotherapy combination known as CHOP suggests that many of those patients can now be considered cured. The analysis is just … Read more